RBX2660, a Donor Stool Product for Fecal Microbiota Transplant, Decreases Recurrent Clostridioides difficile Infection: The First FDA-Approved Live Biotherapeutic Product
Collen R. Kelly, MD and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACGdiscuss “Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection,” by Khanna S, Assi M, Lee C. et al. Drugs [2022; 82: 1527-1538].
